(Q24314623)

GOA release 2020-03-11

response to drug

1 reference

GOA release 2020-03-11

angiogenesis inhibitor

1 reference

S L Maloney

1

0 references

D C Sullivan

2

0 references

S Suchting

3

0 references

J M J Herbert

4

0 references

E M Rabai

5

0 references

Z Nagy

6

0 references

J Barker

7

0 references

S Sundar

8

0 references

R Bicknell

British Journal of Cancer

9

0 references

language of work or name

English

0 references

publication date

15 September 2009

0 references

published in

0 references

volume

101

0 references

page(s)

957-66

0 references

issue

6

0 references

cites work

Induction of the interferon response by siRNA is cell type- and duplex length-dependent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Formation of stable microspikes containing actin and the 55 kDa actin bundling protein, fascin, is a consequence of cell adhesion to thrombospondin-1: implications for the anti-adhesive activities of thrombospondin-1

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Sorafenib in lung cancer: clinical developments and future directions

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

The evolving role of thrombospondin-1 in hemostasis and vascular biology

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

The role of thrombospondin-1 in tumor progression.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Angiogenesis and angiogenesis inhibitors in cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Trials of adjuvant chemotherapy in colorectal cancer.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Role of thrombospondin in hemostasis and cell adhesion

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Thrombospondin: phenomenology to function

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Radiotherapeutic enhancement by razoxane

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Proceedings: Analysis of the antimetastatic action of the antimitotic agent ICRF 159

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane

30 May 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605203

Antitumour Activity in a Series of bisDiketopiperazines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605203

Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells--transcriptional activation and messenger RNA stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605203

The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605203

Histological analysis of the antimetastatic effect of (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2743367

Control of Malignant Metastases by ICRF 159

29 November 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605203

Thrombospondin, a potentiator of tumor cell metastasis

21 January 2018

1 reference

12 December 2020

Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives

1 reference

12 December 2020

Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1

1 reference

12 December 2020

Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane

1 reference

12 December 2020

Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma

1 reference

12 December 2020

A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis

1 reference

12 December 2020

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

12 December 2020

Inhibition of Metastatic Spread by I.C.R.F. 159: Selective Deletion of a Malignant Characteristic

1 reference

12 December 2020

Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192

1 reference

12 December 2020

Influence of ICRF-159 or ICRF-186 on cytotoxicity of daunorubicin and doxorubicin

1 reference

12 December 2020